Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855926 | 0.82 | TRPV1 (0.37) | TRPV1SRD5A1ACHECYP11B1CYP11B2 | |
| SCHEMBL1866161 | 0.82 | TRPV1 (0.37) | TRPV1SRD5A1ACHECYP11B1CYP11B2 | |
| SCHEMBL1856329 | 0.82 | TRPV1 (0.37) | TRPV1SRD5A1ACHECYP11B1CYP11B2 | |
| SCHEMBL5690949 | 0.82 | TRPV1 (0.37) | TRPV1SRD5A1ACHECYP11B1CYP11B2 | |
| SCHEMBL24452647 | 0.76 | PNMT (0.53) | TRPV1SRD5A1CYP11B1CYP11B2PNMT | |
| SCHEMBL1863996 | 0.76 | PNMT (0.53) | TRPV1SRD5A1CYP11B1CYP11B2PNMT | |
| SCHEMBL15086540 | 0.76 | PNMT (0.53) | TRPV1SRD5A1CYP11B1CYP11B2PNMT | |
| SCHEMBL29495985 | 0.76 | PNMT (0.53) | TRPV1SRD5A1CYP11B1CYP11B2PNMT | |
| Hydrochloric Acid SCHEMBL3588397 | 0.74 | PNMT (0.51) | TRPV1SRD5A1CYP11B1CYP11B2PNMT | |
| Hydrochloric Acid SCHEMBL16536351 | 0.74 | PNMT (0.51) | TRPV1SRD5A1CYP11B1CYP11B2PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-102617464-A | fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor | ABBOTT LAB | 2012-08-01 | — | — | CN | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2017265-B1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101445501-A | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| CN-1835924-A | Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor | ABBOTT LAB (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | IDH1 4687/4885TRPV1 2/4885SRD5A1 487/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | IDH1 4660/4885TRPV1 2/4885SRD5A1 475/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | IDH1 4687/4885TRPV1 2/4885SRD5A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.